Julius Juaréz

1.3k total citations
19 papers, 991 citations indexed

About

Julius Juaréz is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Julius Juaréz has authored 19 papers receiving a total of 991 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 10 papers in Oncology and 7 papers in Hematology. Recurrent topics in Julius Juaréz's work include Chemokine receptors and signaling (10 papers), Immunotherapy and Immune Responses (7 papers) and Hematopoietic Stem Cell Transplantation (6 papers). Julius Juaréz is often cited by papers focused on Chemokine receptors and signaling (10 papers), Immunotherapy and Immune Responses (7 papers) and Hematopoietic Stem Cell Transplantation (6 papers). Julius Juaréz collaborates with scholars based in Australia, Sweden and United States. Julius Juaréz's co-authors include Linda J. Bendall, Rana Baraz, Kenneth F. Bradstock, David Gottlieb, K. F. Bradstock, Ken Bradstock, Aileen Dela Peňa, Hassan M. Naif, Anthony L. Cunningham and Dominic E. Dwyer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and The Journal of Immunology.

In The Last Decade

Julius Juaréz

19 papers receiving 975 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julius Juaréz Australia 14 474 381 329 231 157 19 991
A Zander Germany 17 273 0.6× 420 1.1× 465 1.4× 317 1.4× 102 0.6× 51 1.1k
Nahoko Suzuki Japan 8 505 1.1× 393 1.0× 422 1.3× 382 1.7× 37 0.2× 11 1.1k
Federico Simonetta Switzerland 22 945 2.0× 562 1.5× 266 0.8× 268 1.2× 87 0.6× 82 1.5k
J. Joseph Melenhorst United States 18 624 1.3× 348 0.9× 275 0.8× 249 1.1× 56 0.4× 32 1.0k
I L Wolvers-Tettero Netherlands 16 436 0.9× 234 0.6× 277 0.8× 157 0.7× 66 0.4× 22 1.0k
Sabine Huenecke Germany 19 711 1.5× 504 1.3× 309 0.9× 197 0.9× 21 0.1× 53 1.2k
Amparo Sempere Spain 20 272 0.6× 382 1.0× 405 1.2× 337 1.5× 27 0.2× 58 1.4k
Brian H. Santich United States 12 390 0.8× 164 0.4× 61 0.2× 200 0.9× 70 0.4× 19 722
Boris Calmels France 20 345 0.7× 407 1.1× 718 2.2× 504 2.2× 26 0.2× 78 1.4k

Countries citing papers authored by Julius Juaréz

Since Specialization
Citations

This map shows the geographic impact of Julius Juaréz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julius Juaréz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julius Juaréz more than expected).

Fields of papers citing papers by Julius Juaréz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julius Juaréz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julius Juaréz. The network helps show where Julius Juaréz may publish in the future.

Co-authorship network of co-authors of Julius Juaréz

This figure shows the co-authorship network connecting the top 25 collaborators of Julius Juaréz. A scholar is included among the top collaborators of Julius Juaréz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julius Juaréz. Julius Juaréz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Boden, Elisa K., et al.. (2023). Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells. Inflammatory Bowel Diseases. 30(5). 704–717. 2 indexed citations
2.
Heuts, Frank, Dolores Gavier‐Widén, Berit Carow, et al.. (2013). CD4+cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proceedings of the National Academy of Sciences. 110(16). 6482–6487. 46 indexed citations
3.
Welschinger, Robert, et al.. (2012). Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Experimental Hematology. 41(3). 293–302.e1. 55 indexed citations
4.
Hoang, Anh Thu Nguyen, Puran Chen, Julius Juaréz, et al.. (2011). Dendritic cell functional properties in a three-dimensional tissue model of human lung mucosa. American Journal of Physiology-Lung Cellular and Molecular Physiology. 302(2). L226–L237. 47 indexed citations
5.
Juaréz, Julius, Nadia Harun, Marilyn Thien, et al.. (2011). Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood. 119(3). 707–716. 106 indexed citations
6.
Harun, Nadia, Marilyn Thien, Julius Juaréz, Kenneth F. Bradstock, & Linda J. Bendall. (2010). S1P1 Agonists for Use as Adjunct Mobilizing Agents. Blood. 116(21). 826–826. 5 indexed citations
7.
Hoang, Anh Thu Nguyen, Hao Liu, Julius Juaréz, et al.. (2010). Stromal Cell-Derived CXCL12 and CCL8 Cooperate To Support Increased Development of Regulatory Dendritic Cells Following Leishmania Infection. The Journal of Immunology. 185(4). 2360–2371. 24 indexed citations
9.
Jacobson, S., Frank Heuts, Julius Juaréz, et al.. (2009). Alloreactivity but Failure to Reject Human Islet Transplants by Humanized Balb/c/Rag2−/−gc−/−Mice. Scandinavian Journal of Immunology. 71(2). 83–90. 11 indexed citations
10.
Juaréz, Julius, Marilyn Thien, Aileen Dela Peňa, et al.. (2009). CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. British Journal of Haematology. 145(4). 491–499. 29 indexed citations
11.
Juaréz, Julius, Aileen Dela Peňa, Rana Baraz, et al.. (2007). CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 21(6). 1249–1257. 109 indexed citations
12.
13.
Bendall, Linda J., Rana Baraz, Julius Juaréz, Wei Shen, & Kenneth F. Bradstock. (2005). Defective p38 Mitogen-Activated Protein Kinase Signaling Impairs Chemotaxic but not Proliferative Responses to Stromal-Derived Factor-1α in Acute Lymphoblastic Leukemia. Cancer Research. 65(8). 3290–3298. 51 indexed citations
14.
Juaréz, Julius, John Hewson, Adam Cisterne, et al.. (2005). CXCR4 Antagonists Mobilize Acute Lymphoblastic Leukemia Cells into the Peripheral Blood and Inhibit Engraftment in Mice.. Blood. 106(11). 4592–4592. 6 indexed citations
15.
Juaréz, Julius, Linda J. Bendall, & Ken Bradstock. (2004). Chemokines and their Receptors as Therapeutic Targets: The Role of the SDF-1 / CXCR4 Axis. Current Pharmaceutical Design. 10(11). 1245–1259. 98 indexed citations
16.
Juaréz, Julius & Linda J. Bendall. (2004). SDF-1 and CXCR4 in normal and malignant hematopoiesis.. PubMed. 19(1). 299–309. 64 indexed citations
17.
Juaréz, Julius, K. F. Bradstock, David Gottlieb, & Linda J. Bendall. (2003). Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia. 17(7). 1294–1300. 143 indexed citations
18.
Cunningham, Anthony L., et al.. (2000). The level of HIV infection of macrophages is determined by interaction of viral and host cell genotypes. Journal of Leukocyte Biology. 68(3). 311–317. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026